Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

WIB_icon

Early-Phase Trial Shows Venetoclax Plus HMA Has High Response Rates in Older Patients With...

In a phase Ib dose-escalation and dose-expansion study published in Blood, two-thirds of older patients with acute myeloid leukemia (AML) responded to the combination...

Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety

Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...
WIB_icon

Next-Generation Sequencing MRD Assessment Valuable Tool in AML Management

Assessing minimal residual disease (MRD) using next-generation sequencing (NGS) in patients with acute myeloid leukemia (AML) prior to undergoing allogeneic hematopoietic cell transplantation (alloHCT)...

Demystifying Epigenetics in Hematology

In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...

Phase I Trial Shows Activity of Single-Agent Ivosidenib in IDH1-Mutated AML

Ivosidenib was safe and associated with remissions, transfusion independence, and molecular remissions in patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML), according...

FDA Approves Second Filgrastim Biosimilar

Filgrastim-aafil received approval from the U.S. Food and Drug Administration (FDA), making it the second approved biosimilar version of filgrastim. The treatment was given...

European Commission Approves CPX-351 for Two Types of AML

The European Commission (EC) has approved CPX-351 for the treatment of adult patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid...

FDA Approves Ivosidenib for Previously Treated, IDH1-Mutated AML

The FDA approved ivosidenib, a small-molecule IDH1 inhibitor, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and an...

APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML

In a small phase IB/II trial presented at the 23rd Congress of the European Hematology Association, all four evaluable patients with TP53-mutant myelodysplastic syndromes...

Somatic Mutations and Co-Mutations Predict AML Risk in Women

According to results from a deep-sequencing analysis published in Nature Medicine, women with mutations of the TP53 and IDH genes in the absence of...
Advertisement

Current Issue

December 2018, Volume 4, Issue 14

This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, a preview of 2018 ASH Annual Meeting, and more.